Abstract: This application provides a packaging structure, including an antenna in package and a radio frequency chip that are packaged together, where the antenna in package is fastened on the radio frequency chip. The antenna in package includes a radiator and at least two feeding parts, the at least two feeding parts are electrically connected to the radio frequency chip, the radio frequency chip is configured to receive or transmit a radio frequency signal, and at least one of the at least two feeding parts provides differential feeding for the radiator. This application further provides a network device and a terminal device, to reduce an antenna size and make the antenna easier to mount.

Abstract: The invention provides a glutamate decarboxylase mutant with improved pH tolerance and use thereof in synthesis of gamma-aminobutyric acid. The mutant is obtained by mutating glutamate decarboxylase having an amino acid sequence as shown in SEQ ID NO. 3. The enzyme activity of the mutant at pH 6.5 is improved to 178% of the original enzyme (SEQ ID NO. 3). The final yield of 1000 g of substrate fed in batches in a 5L tank for 12 h is up to 688.13 g/L, which is about 52% higher than the productivity of the original glutamate decarboxylase. The final molar conversion rate can reach 98.2%. The invention not only broadens the enzyme activity of GAD under the optimum pH, but also broadens the enzyme activity of GAD under the neutral pH, and enhances the capability of the GAD to synthesize gamma-aminobutyric acid, and therefore is more suitable for industrial production.

Abstract: Provided are hybrid tRNA/pre-miRNA molecules, e.g., comprising a single tRNA and one, two or more pre-miRNA molecules, useful for the production and therapeutic delivery of an inserted RNA sequence, e.g., one or more miRNAs. Also provided are liposomes and nanoparticles that include the hybrid tRNA/pre-miRNA molecules. Methods of treating cancer by administration of the hybrid tRNA/pre-miRNA molecules are also provided.

Abstract: Provided is a terminal device, which includes: a light-emitting layer and a cover plate, camera unit; the light-emitting layer includes a first light-emitting layer and a second light-emitting layer; when the first light-emitting layer is located at a first preset position, a first orthographic projection area of the first light-emitting layer in a first direction coincides with a second orthographic projection area of the camera unit, wherein the first direction a direction pointing from the light-emitting layer to the cover plate; and when the first light-emitting layer is located at a second preset position, a third orthographic projection area of the light-emitting layer does not coincide with at least part of the second orthographic projection area.

Abstract: A tofu press includes: an open container, a foldable plate, a pressing plate, a spring assembly, and an end cover, where the foldable plate is configured to be placed at a bottom of the open container, the foldable plate includes a bottom plate and lateral plates disposed at two sides of the bottom plate, the lateral plates are perpendicular to and connected to the bottom plate, the pressing plate is configured to cover and press a top of the bottom plate, a bottom end of the spring assembly is configured to press the pressing plate, and the spring assembly is fixedly connected to the end cover; and the pressing plate, the lateral plates, the bottom plate, and two faces of the open container form a compression operating area. The tofu press ensures uniform pressing at the time of pressing a food material to dehydrate.

Abstract: A distributed computing system for product defect analysis is disclosed. The distributed computing system for product defect analysis includes a computing cluster for processing product manufacturing messages, a computing cluster for identifying product defect, a product image database, and a client device.

Abstract: The present disclosure provides a recombinant nucleic acid of Escherichia coli, a recombinant E. coli, a culturing method thereof, and a method for biosynthesizing L-threonine thereby, and relates to the technical field of bioengineering. The recombinant nucleic acid of E. coli of the present disclosure, including the gene encoding phosphoenolpyruvate carboxykinase (pck), the gene encoding pyruvate carboxylase (pyc) and the gene encoding threonine operon, is transformed into E. coli to obtain a recombinant E. coli LMT4 strain that takes glucose as a substrate. Using the LMT4 for fermentative production may significantly improve the L-threonine yield and glucose conversion rate, laying a foundation for the industrial production of L-threonine.

Abstract: The present disclosure provides a Bacillus subtilis strain, a recombinant B. subtilis strain and use thereof, belongs to the technical field of microbial fermentation. B. subtilis strain RF1-6 provided by the present disclosure is a mutant strain with the highest riboflavin yield screened by gene modification and mutagenesis using a high riboflavin-producing strain RF1 as a starting strain, deposited at China Center for Type Culture Collection (CCTCC) under accession number M 2022565. Riboflavin yield can be increased by 22.8% compared with that of the high riboflavin-producing strain RF1.

Abstract: A core holder and a prediction method for starting pressure gradient of shale oil based on the core hold are provided. The core holder includes an inlet plug, an outlet plug, a core accommodating cavity disposed between the inlet plug and the outlet plug and used for accommodating the shale oil, a rubber gasket disposed between the outlet plug and the core accommodating cavity, and a microinjector including a microinjector needle portion that passes through the outlet plug and the rubber gasket in sequence to be in contact with the shale oil in the core accommodating cavity. The core holder and the method can solve problems that movable oil volume of a low-porosity, low-permeability and small-volume rock sample and a shale rock sample cannot be accurately measured, and that a movable scale and a starting pressure gradient of the shale oil cannot be measured.

Abstract: The present disclosure provides systems and methods for the recovery of protein species from wet mill grain process streams. Systems and methods of the present disclosure may be integrated with a wet mill grain process to separate out protein species that may limit efficiency of the grain process and produce one or more product streams comprising these separated protein species. A feed stream may be fractionated by at least two membranes into retentate and permeate streams. Removing larger proteins through the membrane fractionation may allow previously soluble prolamin products in the permeate stream(s) to precipitate. The recovered protein species may include prolamin, such as zein from a corn grain feed.

Abstract: The present invention relates to the field of organic electroluminescent devices. Disclosed are a compound containing a 1,3-diketone ligand and an application thereof, and an organic electroluminescent device. The compound has the structure as represented by formula Ir(LA)(LB)2; LA has the structure as represented by formula (IA); LB has the structure as represented by formula (IB), the structure as represented by LB310, the structure as represented by LB311, the structure as represented by LB312, the structure as represented by LB313, or the structure as represented by LB314. The compound containing a 1,3-diketone ligand provided by the present invention has the advantages of low synthesis difficulty and easy to purify, has excellent illumination performance as an organic electrophosphorescent material, and can prolong the service life of the device, increase the solubility of the phosphorescent material, and decrease the probability of triplet-triplet annihilation.

Abstract: An N-aromatic amide compounds with formula (I) is disclosed. The definitions of R1, R2, R3, R4, R5, R6, W1, W2 and W3 in the formula are the same as those in the description.

Abstract: The present disclosure provides a marker and use thereof in predicting a possibility of a subject with diabetes. The marker described may include at least one of ?-hydroxybutyric acid (?-HB), 1,5-anhydroglucitol (1,5-AG), asymmetric dimethylarginine (ADMA), cystine, ethanolamine, taurine, L-leucine, L-tryptophan, hydroxylysine, and L-aspartate. The possibility of the subject with diabetes may be predicted using a prediction model (e.g., prediction models 2-5) related to the marker based on a concentration of the marker. The prediction model 2 is related to ?-HB. The prediction model 3 is related to 1,5-AG and ADMA. The prediction model 4 is related to cystine, ethanolamine, taurine, L-leucine, L-tryptophan and hydroxylysine. The prediction model 5 is related to ?-HB, 1,5-AG, cystine, ethanolamine, taurine and L-aspartate.

Abstract: The present invention relates to N-aromatic amide compounds with formula (I) and/or (II) and preparation methods therefor, pharmaceutical compositions and pharmaceutical formulations containing the compounds with formula (I) and/or (II), and use of the compounds with formula (I) and/or (II) in preparing a medicament for the treatment of diseases related to androgens. The definitions of R1, R2, R3, R4, R5, R6, W1, W2, W3, W4 and W5 in the formula are the same as those in the description. The compounds with the formula (I) and/or (II) are capable of binding to the androgen receptors and have activity for anti-androgen and degrading androgen receptor. The compounds can be used alone or as compositions for the treatment of various androgen-related diseases such as prostate cancer, prostate hyperplasia, breast cancer, bladder cancer, ovarian cancer and the like, and also for the treatment of acne, hirsutism, psilosis and other diseases.

Abstract: An immunoglobulin single variable domain and antigen binding molecule binding BCMA, specifically comprising an immunoglobulin single variable domain and antigen binding molecule, a nucleic acid for encoding the binding molecule, a vector containing the nucleic acid, a cell containing the vector, and a pharmaceutical composition containing the above.

Abstract: The present disclosure provides a marker and use thereof in predicting a possibility of a subject with diabetes. The marker described may include at least one of ?-hydroxybutyric acid (?-HB), 1,5-anhydroglucitol (1,5-AG), asymmetric dimethylarginine (ADMA), cystine, ethanolamine, taurine, L-leucine, L-tryptophan, hydroxylysine, and L-aspartate. The possibility of the subject with diabetes may be predicted using a prediction model (e.g., prediction models 2-5) related to the marker based on a concentration of the marker. The prediction model 2 is related to ?-HB. The prediction model 3 is related to 1,5-AG and ADMA. The prediction model 4 is related to cystine, ethanolamine, taurine, L-leucine, L-tryptophan and hydroxylysine. The prediction model 5 is related to ?-HB, 1,5-AG, cystine, ethanolamine, taurine and L-aspartate.

Abstract: Provided are hybrid tRNA/pre-microRNA and tRNA molecules and their use in methods of preventing and treating hepatocellular carcinoma (HCC). In some embodiments, provided are polynucleotides that include a tRNA operably linked to one or more pre-microRNA (pre-miRNA), where the tRNA and/or pre-miRNA are operably linked to one or more inserted RNA molecules that inhibit the growth or proliferation of a hepatocellular carcinoma (HCC) cell.

Abstract: A method and device for detecting a defect and method for training a model are provided. The method for detecting the defect includes: acquiring a sample data set and identifying feature information of the sample data set; acquiring an initial model; configuring a training parameter based on the feature information; obtaining a target model by training, according to the training parameter, the initial model with the sample data set; and obtaining defect information of a product by inputting real data of the product into the target model. The training parameter includes at least one of a learning rate descent strategy, a total number of training rounds and a test strategy, the learning rate descent strategy includes a number of learning rate descents and a round number when a learning rate descends, and the test strategy includes a number of tests and a round number when testing.